Editorial
CFC transition: the Emperor's new clothes. Each class of drug deserves a delivery system that meets its own requirements
| The first 150 words of the full text of this article appear below. |
It is likely that two related but very different events during this coming year will form milestones in the history of aerosol therapy. One is likely to represent a genuine advance, ushering a new era in which aerosol delivery systems will be used to deliver potent systemically acting drugs via the lungs. The other will be the culmination of an enormously expensive exercise aimed at perpetuating inappropriate technology.
It seems probable that, during the later part of 2000, the FDA will
grant a licence to deliver insulin as an aerosol. The most exciting
aspect of this is that, for the first time in half a century, an
aerosol delivery system has been developed specifically to fulfil a
specific task.1 The biggest market in North America for
inhaled insulin is likely to be in the treatment of type II diabetes
and, although the potential for significant adverse events related to
swings in
This article has been cited by other articles:
-
Morice, A H, Kastelik, J A
(2003). Cough * 1: Chronic cough in adults. Thorax
58: 901-907
[Abstract] [Full Text] -
BROCKLEBANK, D, WRIGHT, J
(2001). CFC transition. Thorax
56: 740a-740
[Full Text] -
WOODCOCK, A, MORICE, A H, EVERARD, M L
(2001). CFC transition. Thorax
56: 501-501
[Full Text]
Register for free content
The full back archive is now available for all BMJ Journals. Institutional subscribers may access the entire archive as part of their subscription. Personal subscribers will also have access to all content when logged in. Non-subscribers who register have free access to all articles published before 2006 right back to volume 1 issue 1. Register here to access the free archive of all BMJ Journals.
Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.
